US5356635A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Carbohydrate glass matrix for the sustained release of a therapeutic agent
Assignee: Biogen MA Inc
•
Filing: 1993-07-13
•
Granted: 1994-10-18
•
Expires: 2013-07-13
Abstract
Abstract A composition for the sustained release of a biologically active therapeutic agent wherein the matrix of the sustained release composition is composed of an amorphous carbohydrate glass matrix comprising a suitable carbohydrate and an agent which retards the recrystallization of the carbohydrate and a biologically active therapeutic agent and a water-insoluble wax dispersed throughout the matrix. Biologically active therapeutic agents which can be incorporated into the carbohydrate glass matrix include prolactin, growth hormones, serum albumins, growth factors or any biologically active fragment or recombinant form thereof.
Inventors
- 👤 Siva N. Raman
- 👤 John P. Cunningham
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:14
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027; A61K9/2013; A61K9/2018
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
38 words
A sustained release composition comprising an amorphous carbohydrate glass matrix, a biologically active therapeutic agent and a hydrophobic substance, where the carbohydrate glass matrix comprises a carbohydrate and an agent which retards recrystallization of the carbohydrate glass matrix.
Claim 2
Dependent Claim
38 words
A sustained release composition comprising an amorphous carbohydrate glass matrix, a biologically active therapeutic agent and a hydrophobic substance, where the carbohydrate glass matrix comprises a carbohydrate and an agent which retards recrystallization of the carbohydrate glass matrix.
Claim 3
Independent Claim
59 words
A method of administering a biologically active therapeutic agent to a mammal comprising implanting a sustained release composition subcutaneously into said mammal wherein the composition comprises an amorphous glass carbohydrate matrix, a biologically active therapeutic agent and a hydrophobic substance, where the carbohydrate glass matrix comprises a carbohydrate and an agent which retards recrystallization of the carbohydrate glass matrix.
Claim 4
Independent Claim
59 words
A method of administering a biologically active therapeutic agent to a mammal comprising implanting a sustained release composition subcutaneously into said mammal wherein the composition comprises an amorphous glass carbohydrate matrix, a biologically active therapeutic agent and a hydrophobic substance, where the carbohydrate glass matrix comprises a carbohydrate and an agent which retards recrystallization of the carbohydrate glass matrix.
Claim 5
Dependent Claim
36 words
A sustained release composition according to claim 1, wherein the amorphous carbohydrate matrix comprises from about 50%-75% by weight of the matrix and the recrystallization retarding agent comprises from about 15%-40% by weight of the matrix.
Claim 6
Dependent Claim
15 words
A sustained release composition according to claim 1, wherein the hydrophobic substance is a wax.
Claim 7
Dependent Claim
28 words
A sustained release composition according to claim 4, wherein the wax comprises white beeswax, yellow beeswax, candelilla wax, carnauba wax, vegetable waxes, castor wax or cetyl esters wax.
Claim 8
Dependent Claim
20 words
A sustained release composition according to claim 1, wherein the hydrophobic substance comprises cholesterol, fatty acid esters or fatty acids.
Claim 9
Dependent Claim
24 words
A sustained release composition according to claim 1, wherein the hydrophobic substance comprises from about 5% to about 25% by weight of the composition.
Claim 10
Dependent Claim
17 words
A sustained release composition according to claim 1, wherein the carbohydrate comprises sucrose, lactose, maltose or cellobiose.
Claim 11
Dependent Claim
29 words
A sustained release composition according to claim 1, wherein the amorphous carbohydrate matrix comprises from about 60% by weight to about 90% by weight of the sustained release composition.
Claim 12
Dependent Claim
18 words
A sustained release composition according to claim 1, wherein the therapeutic agent comprises a polypeptide, vitamin or antibiotic.
Claim 13
Dependent Claim
27 words
A sustained release composition according to claim 10, wherein the polypeptide comprises prolactin, serum albumins, somatotropins, growth factors or any biologically active fragment or recombinant form thereof.
Claim 14
Dependent Claim
24 words
A sustained release composition according to claim 11, wherein the therapeutic agent comprises from about 2% to about 20% by weight of the composition.
Claim 15
Dependent Claim
20 words
A sustained release composition of claim 11, wherein the serum albumin comprises bovine, ovine, porcine, avian or human serum albumin.
Claim 16
Dependent Claim
19 words
A sustained release composition according to claim 11, wherein the somatotropin comprises bovine, ovine, porcine, arian or human somatotropin.
Claim 17
Dependent Claim
42 words
A sustained release composition according to claim 11, wherein the growth factor comprises epidermal growth factor, insulin-like growth factor I, insulin-like growth factor II, fibroblast growth factor, transforming growth factor alpha, transforming growth factor beta, platelet-derived growth factor or nerve growth factor.
Claim 18
Dependent Claim
28 words
A sustained release composition according to claim 1, wherein the recrystallization retarding agent comprises polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycols, maltodextrins, sodium lauryl sulfate, oleyl alcohol or stearyl alcohol.
Claim 19
Dependent Claim
52 words
A sustained release composition according to claim 1, wherein the amorphous carbohydrate glass matrix comprises from about 60%-90% by weight of the composition; the biologically active therapeutic agent comprises from about 2%-20% by weight of the composition; and the wax comprises from about 5% to about 25% by weight of the composition.
Claim 20
Dependent Claim
21 words
A sustained release composition comprising a mixture of recombinant porcine somatotropin; polyvinylpyrrolidone, and beeswax dispersed in an amorphous sucrose glass matrix.
Claim 21
Dependent Claim
21 words
A sustained release composition comprising a mixture of recombinant porcine somatotropin; polyvinylpyrrolidone, and beeswax dispersed in an amorphous sucrose glass matrix.
Claim 22
Independent Claim
137 words
A method for preparing a sustained release composition comprising: a. Mixing an aqueous sucrose solution with an aqueous solution of polyvinylpyrrolidone; b. heating the mixture at a temperature of from about 115° C. to about 118° C. to evaporate a sufficient amount of water such that the mixture becomes viscous; c. cooling the viscous mixture to a temperature of from about 60° C. to about 70° C.; d. kneading a zinc complex of recombinant porcine somatotropin and beeswax with the viscous mixture of sucrose and polyvinylpyrrolidone; e. extruding the viscous mixture of sucrose, polyvinylpyrrolidone, beeswax and somatotropin to form rods; f. cutting the rods to form short cylindrical sections; and g. cooling the short cylindrical sections to form sustained release cylinders having an amorphous sucrose and polyvinylpyrrolidone glass matrix and somatotropin and beeswax dispersed throughout the matrix.
Claim 23
Independent Claim
137 words
A method for preparing a sustained release composition comprising: a. Mixing an aqueous sucrose solution with an aqueous solution of polyvinylpyrrolidone; b. heating the mixture at a temperature of from about 115° C. to about 118° C. to evaporate a sufficient amount of water such that the mixture becomes viscous; c. cooling the viscous mixture to a temperature of from about 60° C. to about 70° C.; d. kneading a zinc complex of recombinant porcine somatotropin and beeswax with the viscous mixture of sucrose and polyvinylpyrrolidone; e. extruding the viscous mixture of sucrose, polyvinylpyrrolidone, beeswax and somatotropin to form rods; f. cutting the rods to form short cylindrical sections; and g. cooling the short cylindrical sections to form sustained release cylinders having an amorphous sucrose and polyvinylpyrrolidone glass matrix and somatotropin and beeswax dispersed throughout the matrix.
Claim 24
Independent Claim
59 words
A method of administering a biologically active therapeutic agent to a mammal comprising orally administering a sustained release composition to the mammal where the composition comprises an amorphous carbohydrate glass matrix, a biologically active therapeutic agent and a hydrophobic substance, where the carbohydrate glass matrix comprises a carbohydrate and an agent which retards recrystallization of the carbohydrate glass matrix.
Claim 25
Independent Claim
59 words
A method of administering a biologically active therapeutic agent to a mammal comprising orally administering a sustained release composition to the mammal where the composition comprises an amorphous carbohydrate glass matrix, a biologically active therapeutic agent and a hydrophobic substance, where the carbohydrate glass matrix comprises a carbohydrate and an agent which retards recrystallization of the carbohydrate glass matrix.
References Cited (Backward Citations)
US2413419A
Cited
FR2383659A1
Cited
US4590062A
Cited
US5266333A
Cited
US4671953A
Cited
US4765980A
Cited
US4857506A
Cited
WO1989004689A1
Cited
EP0345628A2
Cited
US5219572A
Cited
WO1991003237A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-10-17 | 1998-04-18 | 1998-10-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-10-17 | 2002-04-18 | 2002-10-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-10-17 | 2006-04-18 | 2006-10-18 | $7700.00 | Window Closed / Lapsed |